Adenocarcinoma of the Urachus: Case Report
DOI:
https://doi.org/10.24915/aup.245Keywords:
Adenocarcinoma, Urachus, Urinary Bladder NeoplasmsAbstract
Urachal adenocarcinoma is a rare malignancy, accounting for approximately one-third of all bladder adenocarcinomas, about 0.01% of all adult tumors, and 0.5% to 2% of all bladder neoplasms.
We present the case of a 70-year-old male referred for evaluation due to hematuria and mucosuria with a two-month evolution.
Imaging studies revealed a nodular lesion at the bladder dome, suggestive of urachal pathology. Urethrocystoscopy identified an exophytic lesion, and biopsy via transurethral resection confirmed the diagnosis of urachal adenocarcinoma. The patient underwent laparoscopic partial cystectomy with en bloc resection of the urachus and umbilicus, combined with bilateral iliac-obturator lymphadenectomy, without complications. Histopathological analysis confirmed a well-differentiated mucinous adenocarcinoma (pT2bN0M0) with negative surgical margins, no umbilical involvement, and no lymph node metastasis. The patient remains under regular clinical and imaging surveillance, including cystoscopy and thoracoabdominopelvic computed tomography scans, with no evidence of recurrence to date.
Although rare, urachal adenocarcinoma should be considered in the differential diagnosis of bladder dome lesions associated with hematuria. Partial cystectomy with concurrent urachal excision and lymphadenectomy represents an effective treatment approach in selected patients. Decisions regarding adjuvant therapy should be individualized. Postoperative surveillance is essential to detect early recurrences and manage residual urinary symptoms, contributing to improved quality of life.
Downloads
References
Wein AJ. Campbell-Walsh-Wein: Urology. 12th ed. Amsterdam: Elsevier; 2020.
Bao B, Hatem M, Wong JK. Urachal adenocarcinoma: a rare case report. Radiol Case Rep. 2017;12:65–69. doi: 10.1016/j.radcr.2016.10.019.
World Health Organization. Tumors classification – Urachal Carcinoma 2022. Geneve: WHO; 2022.
Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. J Urol. 1984;131:1-8. doi: 10.1016/s0022-5347(17)50167-6.
Hamilou Z, North S, Canil C, Wood L, Hotte S, Sridhar SS,et a. Management of urachal cancer: A consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada. Can Urol Assoc J. 2020;14:E57-E64. doi: 10.5489/cuaj.5946
Siefker-Radtke A. Urachal adenocarcinoma: a clinician’s guide for treatment. Semin Oncol. 2012;39:619–24. doi: 10.1053/j.seminoncol.2012.08.011
Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, Zincke H. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006;107: 712-20. doi: 10.1002/cncr.22060.
Lerner SP. Non-urothelial bladder cancer. UpToDate. [accessed Jan 2023] Available at: https://www.uptodate.com/contents/non-urothelial-bladder-cancer
National Comprehensive Cancer Network Guidelines Version 5. New York: NCCN; 2024.
Published
Issue
Section
Copyright (c) 2023 Portuguese Association of Urology

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.